Category: Biotech Investment
-
Overview In biotech due diligence, the stakes are high. While due diligence checklists are crucial for documenting a company’s clinical, scientific, and operational information, they often miss subtle signs of potential failure or untapped breakthroughs. This case study explores how a biotech investor used advanced qualitative analysis to uncover a hidden breakthrough and avoid a…
-
A sample due diligence case from the perspective of PlexoA’s scientific advisory team. Scenario A venture capital (VC) firm is considering a $2M seed investment in a startup developing a bispecific antibody designed to redirect T cells to attack solid tumors. The startup’s lead asset, called TCX-101, binds to a tumor antigen found in ovarian…
-
A sample due diligence case from the perspective of PlexoA’s scientific advisory team. Background A mid-sized pharmaceutical company was scouting new RNA platforms to license for their rare disease pipeline. A biotech startup had caught their attention with a proprietary siRNA delivery system, claiming improved tissue specificity and reduced immune activation. The pharma team was…
-
A sample due diligence case from the perspective of PlexoA’s scientific advisory team. Background An AI-driven drug discovery startup had generated investor buzz by claiming to identify novel therapeutic targets for neurodegenerative diseases using machine learning on multi-omic datasets. The targets were said to be “biologically novel, mechanistically relevant, and druggable.” But when one of…
-
A sample due diligence case from the perspective of PlexoA’s scientific advisory team. Background A venture capital firm was evaluating a CNS-focused biotech startup preparing for its Series A raise. The company claimed to have developed a novel nanoparticle platform that could cross the blood-brain barrier (BBB) and deliver small molecules directly to neural tissues.…